Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Aquestive Therapeutics, Inc. announced an inducement grant for Dr. Matthew Greenhawt, Chief Medical Officer, under its 2022 Equity Inducement Plan, approved by the Compensation Committee [1][2]. Group 1: Inducement Grant Details - Dr. Greenhawt will receive 75,000 Restricted Stock Units (RSUs) and 50,000 non-qualified common stock options, with grants scheduled for March 9, 2026 [2]. - The RSUs and Options will vest 25% after the first and second anniversaries of the grant date, and 50% on the third anniversary, contingent on continued employment [2]. - The Options will have a ten-year term with an exercise price equal to the closing price of the common stock on the grant date [2]. Group 2: Company Overview - Aquestive is a pharmaceutical company focused on innovative science and delivery technologies to improve patients' lives [3]. - The company is a leader in delivering medications via oral film and operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [3]. - It manufactures four commercialized products for licensees globally and has a library of over 20 epinephrine prodrugs for allergy and dermatological indications [3].